Angiosarcoma
MONDO:0016982A malignant tumor arising from the endothelial cells of the blood vessels. Microscopically, it is characterized by frequently open vascular anastomosing and branching channels. The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei. Angiosarcomas most frequently occur in the skin and breast. Patients with long-standing lymphedema are at increased risk of developing angiosarcoma.
Also known as: angiosarcoma, angiosarcoma (disease), blood vessel sarcoma, hemangiosarcoma, hemangiosarcoma, malignant, malignant angioendothelioma, malignant hemangioendothelioma, sarcoma of blood vessel
2886 clinical trials for this condition and its sub-types, 37 tagged with Angiosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Angiosarcoma
-
Kaposi's sarcoma 45 trials
4 sub-types
- Classic Kaposi sarcoma 3 trials
- Endemic Kaposi sarcoma 1 trial
- Iatrogenic Kaposi's sarcoma 1 trial
- Colorectal Kaposi sarcoma 0 trials Sub-types →
-
Skin angiosarcoma 6 trials
-
Breast angiosarcoma 1 trial
-
Angiosarcoma of the scalp 0 trials
-
Aorta angiosarcoma 0 trials
-
Bone angiosarcoma 0 trials
-
Central nervous system angiosarcoma 0 trials
-
Conventional angiosarcoma 0 trials
-
Gallbladder angiosarcoma 0 trials
-
Liver angiosarcoma 0 trials
-
Mediastinum angiosarcoma 0 trials
-
Ovarian angiosarcoma 0 trials
-
Pediatric angiosarcoma 0 trials
-
Prostate angiosarcoma 0 trials
-
Pulmonary artery leiomyosarcoma 0 trials
-
Pulmonary vein leiomyosarcoma 0 trials
-
Spleen angiosarcoma 0 trials
-
Superior vena cava angiosarcoma 0 trials
1 sub-type
- Superior vena cava leiomyosarcoma 0 trials
-
Thyroid gland angiosarcoma 0 trials
Most studied deeper sub-types
-
Can a Blood-Flow-Blocking drug stall a rare sarcoma?
Disease control CompletedResearchers are testing sorafenib, a drug that blocks enzymes tumors need to grow and cuts off their blood supply, in people with angiosarcoma that is locally advanced, has spread, or cannot be removed by surgery. The trial enrolls about 88 participants and measures how many rema…
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could a chemo drug tame rare vascular tumors?
Disease control CompletedThis small pilot study tested the drug eribulin (Halaven) in 13 people with two rare cancers of blood vessels: angiosarcoma and epithelioid hemangioendothelioma (EHE). The goal was to see if the drug could shrink tumors or stop them from growing. Participants had already tried at…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill may keep soft tissue sarcoma in check after chemo
Disease control CompletedThis study tested whether taking anlotinib pills after initial chemotherapy can help keep advanced soft tissue sarcoma from growing. 49 adults with certain types of sarcoma took anlotinib daily. The goal was to see how long the cancer stayed stable and to check safety. Anlotinib …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for rare cancer: drug combo shows promise in advanced angiosarcoma
Disease control CompletedThis study tested whether adding a targeted drug called bevacizumab to standard chemotherapy (paclitaxel) helps control advanced angiosarcoma, a rare cancer of blood vessels. About 70 adults whose cancer had spread or could not be removed by surgery took part. The goal was to see…
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo for blocking blood vessels shows safety in rare vascular conditions
Disease control CompletedThis study looked at the safety of using Lipiodol® Ultra Fluid (a contrast dye) together with surgical glues to block abnormal blood vessels in 132 adults with conditions like hemangiomas or arteriovenous malformations. The procedure was done as part of their regular treatment pl…
Phase 4 • Sponsor: Guerbet • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC